STOCKS TELEGRAPH

Tag: IMMP Stock

  • Immutep Ltd. (IMMP) stock Loses its Gains of the Day during the After Hours

    On March 04, Immutep Ltd. (IMMP) gained 6.18% during the regular session only to lose 6.91% in the after-hours. There is no recent official announcement or SEC filing while the company has three conferences enlisted for March in its schedule.

    During the regular trading session, the stock varied between a range of $2.4701 and $2.8000. At an above-average volume of 319.73K shares, IMMP stock remained in the green during the session as it added $0.16 or 6.18%. At the close of the session, the stock had a price of $2.7500 per share. Following this, the stock reversed its gains as it plunged down to $2.5600 in the after hours.

    The biotechnology company, Immutep Ltd. focuses on cancer and autoimmune diseases treatment development. Currently, the company has a market capitalization of $225.99 million with its 85.41 million outstanding shares.

    IMMP’s Movement

    IMMP stock had recently plunged down to its 52-week low of $2.02 on February 24, as the stock market saw a downtrend amid the escalating Russia-Ukraine conflict. Following this, the stock had been bullish from February 28 till March 3, when it fell prey to profit booking. The stock resumed its bullish course on March 04. But gaining some more during the regular session, the stock once again suffered a decline as it lost more than what is gained. Since there is no official announcement or SEC filing, the stock seems to be reacting to external factors. Thus, IMMP stock might be moving due to social media discussions or stock sentiment.

    In the past five days, the stock has increased by 13.64% while it has declined by 16.16% year to date. Moreover, IMMP stock was able to add a value of 11.79% last year.

    Upcoming Investor Conferences

    The company will be participating in three upcoming investors conferences in March. Firstly, in the 42nd Annual Cowen Health Care Conference which will take place from March 7 to 9, 2022. The company will present as well as take part in 1-on-1 meetings during the conference. Secondly, in the Maxim Growth Conference which will be held from March 28 to 30, 2022. IMMP’s CEO Marc Voigt will deliver a corporate presentation along with participation in a fireside chat at the conference.

    Source: Good Signals

    In addition, as announced on February 18, the company will be presenting new data from its TACTI-002 phase II trial at ESMO’s European Lung Cancer Congress (ELCC) 2022. The event will take place in person and virtually from March 20 to April 2, in Prague, Czech Republic.

  • What’s going on with Immutep Limited (IMMP) stock today?

    What’s going on with Immutep Limited (IMMP) stock today?

    Shares of the Immutep Limited (IMMP) stock were declining today after recording the gain of 11.32% at the previous closing. IMMP stock price saw a downtrend of 5.76% to drop at $3.37 a share as of this writing. We find no news today to link with IMMP stock however it achieved FDA approval for one of its pipeline candidates on April 8, 2021, after which IMMP stock jumped as much as 14.8% during the last trade. Let’s deep dive to explore more of it.

    What’s happening?

    Immutep Limited (IMMP) is a biotech company working on the research and development of various pharmaceutical products for the cure of cancer and various autoimmune diseases. There is no activity by the IMMP stock today to justify the falling stock price but this downtrend might be due to profit takers stepped in.

    Yesterday, On April 8, 2021, IMMP received the FDA approval for its lead product candidate eftilagimod alpha, a soluble LAG-3 protein used to treat recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This fast-track designation approval has been granted after the reporting of phase 2 clinical data by the Immutep in combination with Keytruda, a cancer drug of Merck, to address the unmet medical needs related to HNSCC.

    IMMP entered the second collaboration with Merck on March 16, 2021, in order to evaluate the eftilagimod alpha in combination with Keytruda, a Merck’s cancer drug, in phase 2 clinical trial.

    Prior to FDA approval, on April 7, 2021, IMMP announced that it had been granted patent number EP3317301 by the European patent office. Novartis AG is the co-owner of the patent and the expiry date of  Immutep S.A.S is 28 July 2036.

    Conclusion:

    IMMP stock was down today after enjoying the bullish sentiment at the previous trading session. Currently, we find no products of Immutep in the market and most of its pipeline candidates are in the early stages of development. Immutep partnerships with big companies like Pfizer, Merck, and others are a good sign of its reputation. In a nutshell, investors need to do fundamental as well as technical analysis before adding this stock to their portfolio.

  • Immutep Limited (IMMP) stock Rises over 40% today. Let’s find out why

    Immutep Limited (IMMP) stock Rises over 40% today. Let’s find out why

    Shares of Immutep Limited (IMMP) stock were high in Thursday’s intraday trading after facing the downtrend of 5.73% at the last trade. IMMP stock price saw a surge of 43.33% today to reach $3.76 a share as of this writing.We find no particular activity by the IMMP stock to support this rise. Let’s deep dive to explore more of it.

    What’s happening?

    Immutep Limited (IMMP) is a biotechnology company focused on the research and development of immunotherapeutic products to treat cancer and autoimmune diseases. The rising stock price of IMMP has nothing to do with any specific announcement or press release by Immutep. However some investors believe that this gain is mainly due to the recent positive announcement by the Bristol Myers Squibb related to Phase 2/3 RELATIVITY-047, a trial related to Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab)

    Recent Announcements by IMMP stock.

    On March 16, 2021, IMMP announced the second trial and collaboration agreement with Merck & Co Inc in order to test its lead product for the treatment of the Second Head & Neck Cancer Study.According to this agreement, IMMP will perform a clinical trial called TACTI-003with160 patients of the 1st line head and neck squamous cell carcinoma (HNSCC).IMMP will observe the results by evaluating the efficacy and safety of its lead product eftilagimod alpha along with pembrolizumab, a Merck’s product.

    On March 09, 2021,Immutep secured the second United States patent grant for Eftilagimod Alpha and PD-1 pathway inhibitor which was filed as a  divisional application followed by the parent patent announced on December 30, 2020.This patent will expire on 20 January 2036 and will help in the clinical development programs of the Immutep in the future.

    Conclusion:

    Things are going well for the penny IMMP stock as far as market sentiment is concerned but the gain without any major reason usually doesn’t last for a long time.Investors having long-term prospects usually don’t mind the short-term bulls and bears rather they focus more on the overall development and expansion of the business.

  • Is that why Immutep Limited (NASDAQ: IMMP) is booming and glooming in the Post-market hours?

    Is that why Immutep Limited (NASDAQ: IMMP) is booming and glooming in the Post-market hours?

    Immutep Limited (NASDAQ: IMMP) stock surged 62% to touch $3.4 in the late-hours trading after, a biotech company that explores novel immunotherapy therapies for cancer and autoimmune diseases, confirmed report that EOC Pharma, its Chinese partner, will launch a new Phase II clinical trial in China for up to 152 patients with metastatic breast cancer.

    A randomized, double-blind, placebo-controlled phase II clinical study with study endpoints like progression-free survival, overall survival, and overall response rate would be the EOC Pharma trial, close to Immutep’s AIPAC study. It is planned to take place across 24 months across 20 clinical trial sites in China and test Immutep’s lead candidate medication eftilagimod alpha in conjunction with paclitaxel in patients with HER2-negative/HR-positive metastatic breast cancer who have progression following endocrine therapy.

    The Chinese authoritative body, the Chinese National Medical Goods Administration, has obtained positive technical guidance from EOC Pharma, causing the first patient to be enrolled and dosed in the trial in Q1 of the calendar year 2021.

  • Market Sentiment Mixed but there are Winners

    Market Sentiment Mixed but there are Winners

    The markets are headed to a mixed start to the week. The S&P 500 and the Dow are both in the red with the NASDAQ up marginally. The subdued sentiment is a reflection of activity in the European markets. Stocks in Europe are in the red as data shows a resurgence in COVID-19 cases. Essentially, this means that the world, including the U.S, is yet to fully control the pandemic.

    For the markets, this means a prolonged period of uncertainty and economic weakness. The Federal Reserve has already announced that it was projecting that the COVID-19 would continue to have a negative impact on the economy in the foreseeable future. Investors are looking to a future where subdued economic activity could potentially lead to a correction.

    Nonetheless, the U.S economy continues to show resilience. Even without an economic stimulus package from the government, the U.S economy continues to show signs of recovery in September.  This is an indicator that the underlying fundamentals are strong and that a new stimulus package or a COVIDD-19 vaccine could reignite the economy.

    In this environment of cautious optimism, there are stocks that are outperforming the market by a huge margin. In today’s session, some of the stocks showing signs of a major upside when markets open are as below:

    Immutep Limited [NASDAQ: IMMP]

    Immutep Limited is one of the top performers this morning and is up by close to 20%. This follows the company’s announcement of an improvement in results from stage 1 of its phase 2 TACTI-002 study. The company’s CMO Dr Fredric Triebel stated that by combining efti and pembrolizumab had shown good progress in people with HNSCC and NSCLC. The progress also attracted positive comments from external players. Commenting on it, principal investigator Dr Martin Forster of the University College London Hospital stated the results they received were encouraging.

    ClearOne Inc [NASDAQ: CLRO]

    This is another top performer this morning and is up by over 10%. This comes days after the company announced that it had priced $5.3 million direct offerings as per NASDAQ rule. The company announced that it would use money from the placement as working capital and other corporate purposes.

    Pivotal Investment Corporation II [NYSE: PIC]

    Pivotal Investment Corporation is another top performer this morning and is up by over 20% pre-market. This follows the company’s announcement that it was merging with XL Fleet, a commercial vehicle electrification company for listing on the NYSE. It is an interesting merger given XL’s growing demand and growing revenues.